US Patent

US8080580 — Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives

Method of Use · Assigned to Pfizer Inc · Expires 2030-07-13 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compounds of Formula (I) for the treatment of diseases, conditions, and/or disorders mediated by sodium-glucose transporter inhibitors, specifically SGLT2 inhibitors.

USPTO Abstract

Compounds of Formula (I) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2214 — Steglatro
U-2214 — Steglatro
U-2214 — Steglatro
U-2214 — Steglatro
U-2214 — Steglatro
U-2214 — Steglatro
U-2214 — Steglatro
U-2214 — Steglatro

Patent Metadata

Patent number
US8080580
Jurisdiction
US
Classification
Method of Use
Expires
2030-07-13
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.